187 related articles for article (PubMed ID: 14605881)
1. Feasibility of 186Re-radioimmunotherapy for treatment in an adjuvant setting of colon cancer.
Kinuya S; Yokoyama K; Izumo M; Sorita T; Obata T; Mori H; Shiba K; Watanabe N; Shuke N; Michigishi T; Tonami N
J Cancer Res Clin Oncol; 2003 Jul; 129(7):392-6. PubMed ID: 14605881
[TBL] [Abstract][Full Text] [Related]
2. Radioimmunotherapy with 186Re-labeled monoclonal antibody to treat liver metastases of colon cancer cells in nude mice.
Kinuya S; Yokoyama K; Kawashima A; Izumo M; Sorita T; Obata T; Watanabe N; Shuke N; Bunko H; Michigishi T; Tonami N
Cancer Biother Radiopharm; 2002 Dec; 17(6):681-7. PubMed ID: 12537672
[TBL] [Abstract][Full Text] [Related]
3. Benefits of combined radioimmunotherapy and anti-angiogenic therapy in a liver metastasis model of human colon cancer cells.
Li XF; Kinuya S; Yokoyama K; Koshida K; Mori H; Shiba K; Watanabe N; Shuke N; Michigishi T; Tonami N
Eur J Nucl Med Mol Imaging; 2002 Dec; 29(12):1669-74. PubMed ID: 12458402
[TBL] [Abstract][Full Text] [Related]
4. Rhenium-186-mercaptoacetyltriglycine-labeled monoclonal antibody for radioimmunotherapy: in vitro assessment, in vivo kinetics and dosimetry in tumor-bearing nude mice.
Kinuya S; Yokoyama K; Tega H; Hiramatsu T; Konishi S; Yamamoto W; Shuke N; Aburano T; Watanabe N; Takayama T; Michigishi T; Tonami N
Jpn J Cancer Res; 1998 Aug; 89(8):870-8. PubMed ID: 9765625
[TBL] [Abstract][Full Text] [Related]
5. Optimal timing of administration of hyperthermia in combined radioimmunotherapy.
Kinuya S; Yokoyama K; Hiramatsu T; Konishi S; Watanabe N; Shuke N; Aburano T; Bunko H; Michigishi T; Tonami N
Cancer Biother Radiopharm; 2000 Aug; 15(4):373-9. PubMed ID: 11041022
[TBL] [Abstract][Full Text] [Related]
6. Improved survival of mice bearing liver metastases of colon cancer cells treated with a combination of radioimmunotherapy and antiangiogenic therapy.
Kinuya S; Yokoyama K; Koshida K; Mori H; Shiba K; Watanabe N; Shuke N; Bai J; Michigishi T; Tonami N
Eur J Nucl Med Mol Imaging; 2004 Jul; 31(7):981-5. PubMed ID: 14991242
[TBL] [Abstract][Full Text] [Related]
7. Locoreginal radioimmunotherapy with 186Re-labeled monoclonal antibody in treating small peritoneal carcinomatosis of colon cancer in mice in comparison with 131I-counterpart.
Kinuya S; Yokoyama K; Izumo M; Sorita T; Obata T; Mori H; Shiba K; Watanabe N; Shuke N; Michigishi T; Tonami N
Cancer Lett; 2005 Feb; 219(1):41-8. PubMed ID: 15694663
[TBL] [Abstract][Full Text] [Related]
8. Intraperitoneal radioimmunotherapy in treating peritoneal carcinomatosis of colon cancer in mice compared with systemic radioimmunotherapy.
Kinuya S; Li XF; Yokoyama K; Mori H; Shiba K; Watanabe N; Shuke N; Bunko H; Michigishi T; Tonami N
Cancer Sci; 2003 Jul; 94(7):650-4. PubMed ID: 12841877
[TBL] [Abstract][Full Text] [Related]
9. Beta emitters rhenium-188 and lutetium-177 are equally effective in radioimmunotherapy of HPV-positive experimental cervical cancer.
Phaeton R; Jiang Z; Revskaya E; Fisher DR; Goldberg GL; Dadachova E
Cancer Med; 2016 Jan; 5(1):9-16. PubMed ID: 26625938
[TBL] [Abstract][Full Text] [Related]
10. Experimental radioimmunotherapy with 186Re-MAG3-A7 anti-colorectal cancer monoclonal antibody: comparison with 131I-counterpart.
Kinuya S; Yokoyama K; Kobayashi K; Motoishi S; Onoma K; Watanabe N; Shuke N; Bunko H; Michigishi T; Tonami N
Ann Nucl Med; 2001 Jun; 15(3):199-202. PubMed ID: 11545188
[TBL] [Abstract][Full Text] [Related]
11. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin.
Koppe MJ; Bleichrodt RP; Soede AC; Verhofstad AA; Goldenberg DM; Oyen WJ; Boerman OC
J Nucl Med; 2004 Jul; 45(7):1224-32. PubMed ID: 15235070
[TBL] [Abstract][Full Text] [Related]
12. Cooperative effect of radioimmunotherapy and antiangiogenic therapy with thalidomide in human cancer xenografts.
Kinuya S; Kawashima A; Yokoyama K; Koshida K; Konishi S; Watanabe N; Shuke N; Bunko H; Michigishi T; Tonami N
J Nucl Med; 2002 Aug; 43(8):1084-9. PubMed ID: 12163635
[TBL] [Abstract][Full Text] [Related]
13. Anti-angiogenic therapy and radioimmunotherapy in colon cancer xenografts.
Kinuya S; Kawashima A; Yokoyama K; Kudo M; Kasahara Y; Watanabe N; Shuke N; Bunko H; Michigishi T; Tonami N
Eur J Nucl Med; 2001 Sep; 28(9):1306-12. PubMed ID: 11585288
[TBL] [Abstract][Full Text] [Related]
14. Pharmacologic intervention with angiotensin II and kininase inhibitor enhanced efficacy of radioimmunotherapy in human colon cancer xenografts.
Kinuya S; Yokoyama K; Kawashima A; Hiramatsu T; Konishi S; Shuke N; Watanabe N; Takayama T; Michigishi T; Tonami N
J Nucl Med; 2000 Jul; 41(7):1244-9. PubMed ID: 10914917
[TBL] [Abstract][Full Text] [Related]
15. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
[TBL] [Abstract][Full Text] [Related]
16. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
[TBL] [Abstract][Full Text] [Related]
17. Repeated adjuvant anti-CEA radioimmunotherapy after resection of colorectal liver metastases: Safety, feasibility, and long-term efficacy results of a prospective phase 2 study.
Sahlmann CO; Homayounfar K; Niessner M; Dyczkowski J; Conradi LC; Braulke F; Meller B; Beißbarth T; Ghadimi BM; Meller J; Goldenberg DM; Liersch T
Cancer; 2017 Feb; 123(4):638-649. PubMed ID: 27763687
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the biodistribution and the efficacy of monoclonal antibody 323/A3 labeled with either 131I or 186Re in human ovarian cancer xenografts.
Kievit E; van Gog FB; Schlüper HM; van Dongen GA; Pinedo HM; Boven E
Int J Radiat Oncol Biol Phys; 1997 Jul; 38(4):813-23. PubMed ID: 9240651
[TBL] [Abstract][Full Text] [Related]
19. Radioimmunotherapy of colorectal cancer in small volume disease and in an adjuvant setting: preclinical evaluation in comparison to equitoxic chemotherapy and initial results of an ongoing phase-I/II clinical trial.
Behr TM; Memtsoudis S; Vougioukas V; Liersch T; Gratz S; Schmidt F; Lorf T; Post S; Wörmann B; Hiddemann W; Ringe B; Becker W
Anticancer Res; 1999; 19(4A):2427-32. PubMed ID: 10470170
[TBL] [Abstract][Full Text] [Related]
20. Radioimmunotherapy of colorectal cancer liver metastases: combination with radiotherapy.
Buchegger F; Roth A; Allal A; Dupertuis YM; Slosman DO; Delaloye AB; Mach JP
Ann N Y Acad Sci; 2000 Jun; 910():263-9; discussion 269-70. PubMed ID: 10911919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
